A novel epidermal growth factor receptor inhibitor promotes apoptosis in non–small cell lung cancer cells resistant to erlotinib
T de La Motte Rouge, L Galluzzi, KA Olaussen… - Cancer research, 2007 - AACR
Non–small cell lung cancer (NSCLC) with activating mutations in the epidermal growth
factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib …
factor receptor (EGFR) responds to EGFR tyrosine kinase inhibitors such as erlotinib …
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
Y Gong, R Somwar, K Politi, M Balak… - PLoS …, 2007 - journals.plos.org
Background Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of …
with increased sensitivity of lung cancers to kinase inhibitors like erlotinib. Mechanisms of …
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway
TT Chao, CY Wang, CC Lai, YL Chen, YT Tsai… - … of Pharmacology and …, 2014 - ASPET
Some patients with nonsmall-cell lung cancer (NSCLC) without epidermal growth factor
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
receptor (EGFR) mutations still respond to gefitinib and erlotinib, suggesting that there may …
[HTML][HTML] Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung …
M Wang, J Zhao, LM Zhang, H Li, JP Yu… - Journal of cancer …, 2012 - Springer
Purpose Non-small-cell lung cancer (NSCLC) cells with somatic mutations in epidermal
growth factor receptors (EGFR) are initially susceptible to tyrosine kinase inhibitor (TKI); …
growth factor receptors (EGFR) are initially susceptible to tyrosine kinase inhibitor (TKI); …
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
JA Engelman, K Zejnullahu, CM Gale, E Lifshits… - Cancer research, 2007 - AACR
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are
effective treatments for a subset of non–small cell lung cancers. In particular, cancers with …
effective treatments for a subset of non–small cell lung cancers. In particular, cancers with …
[HTML][HTML] Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa… - International …, 2017 - spandidos-publications.com
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
[HTML][HTML] JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor
F Zhang, W Yang, S Duan, Y Xia, R Zhu, Y Chen - Oncotarget, 2015 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations are responsive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, NSCLC …
mutations are responsive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, NSCLC …
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
K Politi, PD Fan, R Shen… - Disease models & …, 2010 - journals.biologists.com
Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR)
mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and …
mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and …
Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
G Giaccone, Y Wang - Cancer treatment reviews, 2011 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
gefitinib have been incorporated into treatment paradigms for patients with advanced non …
[HTML][HTML] IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
RI Fernando, DH Hamilton, C Dominguez, JM David… - Oncotarget, 2016 - ncbi.nlm.nih.gov
A signaling pathway that is frequently deregulated in human carcinomas and has been
explored as a therapeutic target involves the activation of the epidermal growth factor …
explored as a therapeutic target involves the activation of the epidermal growth factor …
相关搜索
- small cell lung cancer
- lung cancer growth factor
- lung cancer combined erlotinib
- lung cancer acquired resistance
- lung cancer preclinical evaluation
- receptor inhibitor erlotinib
- td 19 erlotinib derivative
- erlotinib resistance egf receptor
- nonsmall cell erlotinib derivative
- erlotinib resistance lung adenocarcinoma
- induction of bim lung adenocarcinomas
- receptor inhibitor growth factor
- erlotinib derivative growth factor
- erlotinib resistance growth factor
- nonsmall cell growth factor
- lung adenocarcinoma growth factor